AlloVir (NASDAQ:ALVR) Reaches New 12-Month Low – Time to Sell?

Shares of AlloVir, Inc. (NASDAQ:ALVR) hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $7.97 and last traded at $8.40, with a volume of 12995 shares. The stock had previously closed at $8.77.

AlloVir Price Performance

The stock has a market capitalization of $985.81 million, a PE ratio of -9.69 and a beta of 0.65. The firm’s 50 day simple moving average is $0.51 and its 200 day simple moving average is $0.69.

AlloVir (NASDAQ:ALVR) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10.

Institutional Investors Weigh In On AlloVir

A hedge fund recently raised its stake in AlloVir stock. Cubist Systematic Strategies LLC increased its holdings in AlloVir, Inc. (NASDAQ:ALVR) by 152.3% in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 49,816 shares of the company’s stock after buying an additional 30,072 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in AlloVir were worth $36,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 66.05% of the company’s stock.

About AlloVir

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.